NICE committee meeting outcome: Melanoma (resected, lymph node, metastatic) – nivolumab (adjuvant) (Review of TA558) [ID1681]

‘A triumph of the professional and patient/public groups working together to get the best outcome for patients’

NICE not only examined the evidence and cost effectiveness for this drug but also importantly listened to comments submitted from stakeholders – including an important testimony from Melanoma Focus (on behalf of the patients and health care professionals), our patron Chris Bryant MP and a joint letter from 55 oncologists and Melanoma UK. This is excellent news for our patients and another important step in improving outcomes for melanoma. 

[Confirmed by Dr Ajaz]